Theres also no set recommendation on what time of day works best
That was kind of the value proposition for many of the clinicians or the patients, Dr
Two drugs are in Phase 3 clinical trials: Eli Lillys GCGR x GIPR x GLP-1R triple agonist, Retatrutide, and Boehringer Ingelheims GCGR x GLP-1R dual agonist, Survodutide
In official Phase 3 trial results from March 2026, the most common side effects remain gastrointestinal (nausea, vomiting), with no widespread clinical signal for major psychiatric shifts
Another question is, will you address a lean body mass loss using semaglutide and tirzepatide
Taking them together allows vitamin C to recycle glutathione, keeping it in its active state to better support your body's defense against oxidative stress